Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancerGlobeNewsWire • 01/12/26
Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA TranscriptSeeking Alpha • 01/09/26
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival BenefitPRNewsWire • 01/06/26
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/25
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual MeetingPRNewsWire • 12/05/25
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers SymposiumPRNewsWire • 12/02/25
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/02/25
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The FenceSeeking Alpha • 11/17/25
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory PlansBenzinga • 11/17/25
Why Jazz (JAZZ) International Revenue Trends Deserve Your AttentionZacks Investment Research • 11/17/25
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric CancerInvestors Business Daily • 11/17/25
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.Barrons • 11/17/25
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal AdenocarcinomPRNewsWire • 11/17/25
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025PRNewsWire • 11/11/25